Margaret Knowles

Discovery-driven research and clinical research have worked together to change the outcomes of many cancer patients. We choose urothelial carcinoma as an example to showcase how recent diagnostic and therapeutic innovations have re-shaped cancer clinical practice. To read this article in full you will need to make a payment Purchase one-time access Read-It-Now Purchase access to all full-text HTML articles for 6 or 36 hr at a low cost. Click here to explore this opportunity.

Bladder cancers, the majority of which are urothelial carcinoma, are the most common urinary tract cancers. There are two major disease types, muscle-invasive and non-muscle-invasive, with distinct pathogenesis pathways, molecular features, and clinical outcomes. Recent genomic and transcriptomic data have significantly improved tumor sub-classification and prognostication for both patient groups and are informing improved approaches to treatment of muscle-invasive disease.